Clear Cell Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Clear Cell Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors [Phase 1]
A Phase 1 study evaluating AB521 as both a single agent and in combination regimens for clear cell renal cell carcinoma and other solid tumo…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma [Phase 1]
A Phase 1 study of UCL70805F in CD70-positive advanced clear cell renal cell carcinoma is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial update for a combination of sasanlimab, palbociclib, and axitinib in metastatic renal cell carcinoma; currently recru…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study [Phase 2]
Phase II clinical trial evaluating AK112 (Yiwoxidan Anti) as monotherapy for metastatic clear cell renal cell carcinoma in patients intolera…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update reports that GI Innovation is studying GI-101 and GI-101A as single agents or in combination with pembrolizumab o…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) [Phase 2]
A randomized Phase 2 trial in first-line advanced renal cell carcinoma compares nivolumab with ipilimumab plus relatlimab versus nivolumab w…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma [Phase 2]
An open-label Phase 2 trial compares the combination of SLC-3010 with Axitinib versus Axitinib alone as second-line therapy for locally adva…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma [Phase 1]
Announces an open-label Phase 1/2 study of NEO-811 for locally advanced or metastatic non-resectable clear cell renal cell carcinoma, curren…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC [Phase 2]
Phase 2 clinical trial evaluating CAIX-targeted PET/CT imaging for residual or recurrent post-ablative clear cell renal cell carcinoma; the …
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC [Phase 3]
Phase 3 clinical trial evaluating Volrustomig with or without Casdatifan against Nivolumab plus Ipilimumab as first-line treatment for advan…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment [Phase 2]
Phase 2 trial evaluating pembrolizumab plus lenvatinib in recurrent clear cell renal cell carcinoma patients who failed prior adjuvant thera…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC [Phase 2]
A Phase 2 study evaluating adaptive immunotherapy with a VEGFR-TKI in patients with advanced renal cell carcinoma has been suspended.
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer [Phase 2]
This Phase 2 clinical trial compares lenvatinib plus everolimus versus cabozantinib for second- or third-line treatment of metastatic clear …
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer [Phase 1]
Phase 1 trial evaluating CBM588 in combination with nivolumab and cabozantinib for advanced or metastatic renal cell carcinoma.
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma [Phase 1]
Xencor's XmAb®819 is being studied in a Phase 1 trial for advanced clear cell renal cell carcinoma and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the combination of cemiplimab and fianlimab in people with clear cell renal …
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating cemiplimab alone or in combination with fianlimab after stereotactic body radiotherapy in patients with cl…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pazopanib hydrochloride in combination with bevacizumab for previously untreated metastatic renal cell…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer [Phase 1]
Phase 1 clinical trial evaluating nivolumab and ipilimumab, with or without the EXL01 live biotherapeutic product, for metastatic renal cell…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
A Mayo Clinic-led clinical trial is evaluating whether tumor-derived extracellular vesicles can noninvasively classify different kidney canc…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma [Phase 2]
This is a Phase II trial update for Ivonescimab in previously treated patients with advanced clear cell renal cell carcinoma, and the study …
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: 177LuPSMA in Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating Lutetium-177 labeled PSMA radioligand (177Lu-PSMA) in advanced renal cell carcinoma. The study is currently active …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC [Phase 2]
Phase 2 neoadjuvant trial evaluating the combination of iparomlimab and tuvonralimab (QL1706) with lenvatinib for clear cell renal cell carc…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC [Phase 2]
Phase 2 trial evaluating pucotenlimab in combination with vorolanib as neoadjuvant therapy for clear cell renal cell carcinoma is currently …
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma
This completed study reports real-world evidence on using tivozanib as first-line therapy for metastatic clear cell renal cell carcinoma.